β-catenin/CBP-IN-1 (extracted from the patent WO2014092154A1) is a novel highly potent and specific CBP/β-catenin antagonis. β-catenin/CBP-IN-1 has the highly potential for the study of liver fibrosis induced by hepatitis virus. References: [1]. Takenao Odagami, et al. Prevention or treatment agent for hepatic fibrosis. Patent WO2014092154A1.

纯度：≥98%

CAS：1198780-38-9